D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE
    4.
    发明申请
    D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE 审中-公开
    用于肝病的卤代吡啶化合物的D-氨基酸磷酸酯原核生物

    公开(公告)号:US20150037282A1

    公开(公告)日:2015-02-05

    申请号:US14448909

    申请日:2014-07-31

    摘要: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.

    摘要翻译: 本文提供了用于治疗病毒感染的化合物,组合物和方法,例如黄病毒科感染,包括HCV感染。 在某些实施方案中,公开了核苷衍生物的化合物和组合物,其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中,化合物是D-氨基酸氨基磷酸酯卤代嘧啶核苷类似物化合物,其显示用于治疗例如人类HCV感染的显着功效和生物利用度。 在某些实施方案中,化合物具有式I:或其药学上可接受的盐,溶剂合物,立体异构形式,互变异构形式或其多晶型,其中:PD,X,R 1,R 2,RA和RB如本文所述。

    DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION
    8.
    发明申请
    DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION 审中-公开
    用于HCV感染的胆固醇化合物

    公开(公告)号:US20140112886A1

    公开(公告)日:2014-04-24

    申请号:US14057998

    申请日:2013-10-18

    摘要: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2′-methyl nucleotides linked according to Formula I: N1-L-N2  (I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N1, L and N2 are as described herein.

    摘要翻译: 本文提供了用于治疗黄病毒科感染(包括HCV感染)的化合物,组合物和方法。 在某些实施方案中,公开了核苷衍生物的化合物和组合物,其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中,化合物包含根据式I连接的两个2'-甲基核苷酸:N1-L-N2(I)或其药学上可接受的盐,酯,溶剂合物,立体异构体,异构形式,互变异构形式或其多晶型; 其中N1,L和N2如本文所述。